The utility of sulfonate salts in drug development

Journal of Pharmaceutical Sciences

Volumn 99, Issue 7, 2010, Pages 2948-2961

  Elder, David P ^a   Delaney, Ed ^b   Teasdale, Andrew ^c   Eyley, Steve ^c   Reif, Van D ^d   Jacq, Karine ^e   Facchine, Kevin L ^f   Oestrich, Rolf Schulte ^g   Sandra, Patrick ^e   David, Frank ^e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Reaction Science Consulting LLC   (United States)

^c ASTRAZENECA   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Research Institute for Chromatography   (Belgium)

^f GLAXOSMITHKLINE   (United States)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alkylators; Crystallinity; Crystallization; Formulation; Hydrates solvates; Hygroscopicity; Morphology; Physicochemical properties; Polymorphism

Indexed keywords

4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; AMIODARONE; ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; AVITRIPTAN; BMS 181885; CARDIOVASCULAR AGENT; COUNTERION; EPHEDRINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCHLORIC ACID; MESYLIC ACID; MISCELLANEOUS DRUGS AND AGENTS; NBI 75043; NELFINAVIR; NEOSTIGMINE; PRALIDOXIME MESILATE; RPR 127963; RUBOXISTAURIN; SIBENADET; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AREA UNDER THE CURVE; CHEMICAL MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRYSTAL STRUCTURE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MANUFACTURE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; GENOTOXICITY; HYDROPHOBICITY; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; NONHUMAN; PARTICLE SIZE; PH; REVIEW; RHEUMATOID ARTHRITIS;

EID: 77953318934     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22058     Document Type: Review

References (64)

1. European Medicines Agency. 2007. Press Release (20th September 2007) CHMP Assessment Report for Viracept, London. EMEA/H/C/164/Z/109. European Medicines Agency Agrees on Action Plan Following the Recall of Viracept and Recommends Suspension of the Marketing Authorisation, London. EMEA/275367/2007.
2. Mesylate Ester Type Impurities Contained in Medicinal Products, Swissmedic Department for Control of the Medicinal Products Market, 23rd October 2007.
3. Guideline on the Limits of Genotoxic Impurities, Committee for Medicinal Products (CHMP), European Medicines Agency, London, 28 June 2006 (CPMP/SWP/5199/02, EMEA/CHMP/QWP/251344/2006).
4. Coordination Group for Mutual Recognition-Human committee (CMDh), Request to Assess the Risk of Occurrence of Contamination with Mesilate Esters and Other Related Compounds in Pharmaceutical, EMEA/CMDh/98694/2008, London, 27th February 2008.
5. CHMP Assessment Report for Viracept, EMEA/CHMP/492059/2007, 20th September 2007.
6. Teasdale A, Eyley S, Delaney E, Jacq K, Taylor-Worth K, Lipczynski A, Reif VD, Elder DP, Facchine K, Golec S, Oestrich RS, Sandra P, David F. 2009. Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid, An Illustrative Example for Sulfonate Ester Impurity Formation. Org Process Res Dev 13:429-433.
7. Berge SM, Bighley LD, Monkhouse DC. 1977. Pharmaceutical salts. J Pharm Sci 66:1-19.
8. Bighley LD, Berge SM, Monkhouse DC. 1995. Salt Forms of Drugs and Absorption. In: Swarbrick J, Boylan JC, editors. Encyclopaedia of pharmaceutical technology, Vol. 13. New York: Marcell-Decker, Inc. pp 453-499.
9. Stahl PH, Wermuth G. 2002. Monographs on acids and bases. In: Stahl PH, Wermuth G, editors. Handbook of Pharmaceutical Salts; Properties, Selection and Use (International Union of Pure and Applied Chemistry), Chapter 12. New York: Wiley-VCH. pp 265-327.
10. Balbach S, Korn C. 2004. Pharmaceutical evaluation of early development candidates "the 100mg approach." Int J Pharm 275:1-12.
11. Gardner CR, Almarsson O, Chen H, Morrisette S, Peterson M, Zhang Z, Wang S, Lemmo A, Gonzales-Zugasti J, Monagle J, Marchionna J, Ellis S, McNulty C, Johnson A, Levinson D, Cima MJ. 2004. Application of a high throughput technologies to drug substance and drug product development. Comp Chem Eng 28:943-953. (Pubitemid 38520951)
12. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR. 2004. High-throughput crystallisation: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 56:275-300. (Pubitemid 38201426)
13. Zhu H, Xu J, Varlashkin P, Long S, Kidd C. 2001. Dehydration, hydration behaviour and structural analysis of fenoprofen calcium. J Pharm Sci 90:845-859. (Pubitemid 32645943)
14. Anderson BD, Flora KP. 1996. Preparation of water soluble compounds through salt formation. In: Wermuth CG, editor. The practices of medicinal chemistry. London: Academic Press. pp 739-754.
15. O'Connor KM, Corrigan OI. 2001. Comparison of the physicochemical properties of the N-(2-hydroxyethyl)pyrroloidine, diethylamine and sodium salt forms of diclofenac. Int J Pharm 226:163-179.
16. Reynolds JEF, editor. 1993. Martindale: The extra pharmacopoeia, 30th edition. London: The Pharmaceutical Press. pp 1-1428.
17. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59:603-616.
18. Lipinski CA, Lombardo F, Dominy BW, Feeny PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 44:3-25. (Pubitemid 27046991)
19. Lipinski CA. 2004. Solubility in water and DMSO: Issues and potential solutions. In: Borchardt RT, Kerns EH, Lipinski CA, Thakker DR, Wang B, editors. Pharmaceutical profiling in drug discovery for lead selection. Arlington, Virginia: AAPS Press. pp 93-125.
20. Serajuddin ATM, Pudipeddi M. 2002. Salt-selection strategies. In: Stahl PH, Wermuth G, editors. Handbook of Pharmaceutical Salts; Properties, Selection and Use (International Union of Pure and Applied Chemistry), Chapter 6. New York: Wiley-VCH. pp 135-160.
21. Chiang P-C, South SA, Daniels JS, Anderson DR, Wene SP, Albin LA, Mourey RJ, Selbo JG. 2009. Aqueous versus nonaqueous salt delivery strategies to enhance oral bioavailability of a mitogen-activated protein kinase-activated protein kinase (MK-2) inhibitor in rats. J Pharm Sci. 98:248-256.
22. Black SN, Collier EA, Davey RJ, Roberts RJ. 2007. Structure, solubility, screening and synthesis of molecular salts. J Pharm Sci 96:1053-1068. (Pubitemid 46797476)
23. Brittain HG. 2007. Pharm Technol Strategy for the Prediction and Selection of Drug Substance Salt Forms 31:78-88.
24. Remenar JF, MacPhee JM, Larsen BK, Tyagi VA, Ho JH, McIlroy DA, Hickey MB, Shaw PB, Almarsson O. 2003. Salt selection and simultaneous polymorphism assessment via high throughput crystallization: The case of sertraline. Org Process Res Dev 7:990-996. (Pubitemid 37543828)
25. Gross TD, Schaab K, Ouellette M, Zook S, Reddy JP, Schurtleff A, Sacaan AI, Alebic-Kolbah T, Bozigan H. 2007. An approach to early phase salt selection: Application to NBI-75043. Org Process Res Dev 11:365-377.
26. Bastin RJ, Bowker MJ, Slater BJ. 2000. Salt selection and optimisation for pharmaceutical new chemical entities. Org Process Res Dev 4:427-435.
27. Stahl PH. 2002. Appendix by Wermuth G. In: Stahl PH, Wermuth G, editors. Handbook of Pharmaceutical Salts; Properties, Selection and Use (International Union of Pure and Applied Chemistry). New York: Wiley-VCH. pp 329-350.
28. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. 2001. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 48:91-114.
29. Airaksinen S, Karjalainen M, Schevchenko A, Westermarck S, Leppa"nen E, Rantanen J, Yliruusi J. 2005. Role of water in the physical stability of solid dosage formulations. J Pharm Sci 94:2147-2165.
30. Elder DP. 1992. PhD thesis entitled, "Physicochemical and Crystallographic Investigations into the Salt Formation of Two Heterocyclic Drugs". University of Edinburgh, UK.
31. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. 2000. Salt form selection and characterisation of LY333531 mesylate monohydrate. Int J Pharm 198:239-247.
32. Lee S, Hoff C. 2002. Large scale aspects of salt formation: Processing of intermediates and final products. In: Stahl PH, Wermuth G, editors. Handbook of Pharmaceutical Salts; Properties, Selection and Use (international Union of Pure and Applied Chemistry), Chapter 8. New York: Wiley-VCH. pp 191-220.
33. Verbeek RK, Kanfer I, Walker RB. 2006. Generic substitution: The use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci 28:1-6.
34. Steele G. Pre-formulation - Candidate Drug Selection, Characterisation and Implications for Product Design, presented at CPS Symposium 2006, Exploiting Emerging Formulation Sciences Technologies for Pharmaceutical and Fine Chemicals Manufacturing, 12-13th October 2006, Singapore, 2006, http://www.ices.a-star.edu.sg/ices/CPSsymposium2006/index.do.
35. Lin S-L, Lachman L, Swartz CJ, Huebner CF. 1972. Preformulation investigation I: Relation of salt forms and biological activity of an experimental hypertensive. J Pharm Sci 61:1418-1422.
36. Chen TK, Thornton D, Ho MYK. 1990. Reduction of dimethyl sulfoxide by dihydrohalide salts of pharmaceuticals. Int J Pharm 59:211-216. (Pubitemid 20146152)
37. Narurkar AN, Purkatystha AR, Sheen P-C. 1985. Effect of various factors on the corrosion and rusting of tooling material used for tablet manufacture.Drug Dev Ind Pharm11:1487-1495.
38. Dressman J, Reppas C. 2007. Drug solubility: How to measure it, how to improve it. Ad Drug Deliv Rev 59:531-532. (Pubitemid 47285411)
39. Gould PL. 1986. Salt selection for basic drugs. Int J Pharm 33:201.
40. Streng WH, His SK, Helms PE, Tan HG. 1984. General treatment of the pH solubility profiles of weak acids and bases and the effects of different salts on the solubility of a weak base. J Pharm Sci 73:1679-1684.
41. Amidon GL, Lennernas H, Shah VP, Crison JRA. 1995. Theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 124:413-420.
42. Li S, Wong S, Sethia S, Almoazen H, Yoshi YM, Serajuddin AT. Investigation and solubility and dissolution of a free base and two different salt forms as a function of pH. Pharm Res 2005. 22:628-635. (Pubitemid 40603261)
43. Creasey NH, Green AL. 1959. 2-Hydroxyiminomethyl-N-methylpyridinium methanesulphonate (P2S), an antidote to organophosphorus poisoning. Its preparation, estimation and stability. J Pharm Pharmacol 11:485-490.
44. Hussain MA, Wu L-S, Koval C, Hurwitz AR. 1992. Parenteral formulation of the kappa agonist analgesic, DuP 747, via Micellar solubilization. Pharm Res 9:750-752.
45. Benneker FBD, Van Dalen F, Lemmens JM, Peters T, Picha F. 4-Phenylpiperidine compounds, WOV 98/56787, 17th December, 1998.
46. Rowe RC, Wakerly MG, Roberts RJ, Grundy RU, Upjohn NG. 1995. Expert systems for parenteral development. PDA J Pharm Sci Technol 49:257-261.
47. Simamora P, Pinsuwan S, Surakitbanharn Y, Yalkowsky SH. 1995. Studies in phlebitis VIII: Evaluations of pH solubilized intravenous dexverapamil formulations. PDA J Pharm Sci Technol 50:123-128. (Pubitemid 26122137)
48. Strickley RG. 2000. Parenteral formulations of small molecules therapeutics marketed in the United States (Part III). PDA J Pharm Sci Technol 54:152-169. (Pubitemid 30321145)
49. Kim Y, Oksanen DA, Massefski W, Jr., Blake JF, Duffy EM, Chruynk B. 1998. Inclusion complexes of Ziprasidone mesylate with β-cyclodextrin sulfobutyl ether. J Pharm Sci 87:1560-1567. (Pubitemid 28559642)
50. Ware EC, Lu DR. 2004. An automated approach to salt selection for new unique trazodone salts. Pharm Res 21:177-184.
51. Stephens VC. US Patent 3,065,261, 1962.
52. Serajuddin ATM, Jarowski CI. 1985. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts: Phenazopyridine. J Pharm Sci 74:142-147. (Pubitemid 15135799)
53. Li S, Doyle P, Metz S, Royce AE, Serajuddin ATM. 2005. Effect of chloride ion on dissolution of different salt forms of haloperidol. J Pharm Sci 94:2224-2231. (Pubitemid 41665282)
54. Perrin J, Vallner J. 1970. The effect of the anion on the absorption of tetracycline from the rat stomach. J Pharm Pharmacol 758-762.
55. Miyazaki S, Oshiba M, Nadai T. 1981. Precaution on use of hydrochloride salts in pharmaceutical formulations. Chem Pharm Bull 70:594-595.
56. Lewis C, Stern KF, Grady JE. 1965. Comparisons of laboratory animals of the antibacterial activity and absorption of lincomycin hexadecylsulfamate and lincomycin hydrochloride. In: Sylvester JC, editor. Antimicrobial agricultural chemotherapym 1964. Washington: American Society of Microbiology. pp 13-17.
57. Rajogopolan N, Dicken CM, Ravin LJ, Randall CS, Krupinski-Olsen R. 1989. Solubility properties of the serotonergic agonist 2,3,4,5-tetrahydro-8- (methylsulfonyl)-1H-3-benazazepin-7-ol. Drug Dev Ind Pharm 15:489-497.
58. Malek P, Kolc J, Herold M, Hoffman J. 1958. Lymphotrophic antibiotics - "Antibiolymphins." In: Welsch H, Marti-Ibanez F, editors. Antibiotics annual, 1957-1958. New York: Medical Encyclopaedia, Inc. pp 546-551.
59. Massey EH. German Ofen. 2,138,049 (3rd February, 1972) through Chem Abs 76: 117507f, 1972.
60. Debs R, Brunette E, Fuchs H, Lin E, Shah M, Hargis A, Montogomery AB. 1990. Biodistribution, tissue reaction, and lung retention of pentamidine aerosolisized as three different salts. Am Rev Respir Dis 142:1164-1167.
61. Müller L, Gocke E, Larson P, Lavé T, Pfister T. Elevated Ethyl Methane Sulfonate (EMS) in Nelfinavir Mesylate (Viracept, Roche): Animal Studies Confirm Toxicity Threshold and Absence of Risk to Patients, Poster LPBE1157, XVII International AIDS Conference, 03-08th August, 2008, Mexico City, Mexico.
62. CPDB. 2008. Carcinogenic Potency Database. Methyl methanesulfonate: http://potency.berkeley.edu/chempages/METHYL%20METHANESULFONATE.html.
63. Yang Q, Haney BP, Vaux A, Riley Da, Heidrich L, He P, Mason P, Tehim A, Fisher Le, Maag H, Anderson Ng. 2009. Controlling the genotoxins ethyl chloride and methyl chloride formed during the preparation of amine hydrochloride salts from solutions of ethanol and methanol. Org Process Res Dev 13:786-791.
64. Emmerson JL, Gibson WR, Anderson RC. 1971. Acute toxicity of propoxyphene salts. Toxicol Appl Pharmacol 19:445-451.